Russia Covid Vaccine Trial

Russia said on Wednesday it planned to export a nasal form of its Sputnik vaccine against COVID-19, which President Vladimir Putin said he had taken as a booster.

The Russian COVID-19 vaccine "Sputnik V" will cost less than USD 10 (about Rs 730) per shot in India and the price is the same for all countries, Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) said on Thursday.

Congress's Rahul Gandhi today aimed a jibe at Prime Minister Narendra Modi, pointing to several nations beginning inoculation for Covid and implying India's journey towards a vaccine is slow. Four nations -- US, UK, China and Russia -- are pressing ahead with vaccination as a new, more infectious mutation of the virus has brought life to a standsti...

Russian coronavirus vaccine developers published fresh results from their trial of the Sputnik V vaccine on Monday based on new data, and said the shot had again been found to be 91.4 per cent effective in providing protection from COVID-19.

The first batch of Russia's Sputnik V vaccine for COVID-19 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine's Phase 2 and Phase 3 human clinical trials will be conducted.

Russia's Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country's sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

Pharmaceutical giant Dr. Reddy's Laboratories today said that it had isolated all its data centre services as a preventive measure following a cyberattack. The drug maker had shut its key plants globally due to the breach at its servers, ET Now had reported, citing sources.

Dr Reddy's Share Price: The stock rose by Rs 131.15 to Rs 5,213.50 apiece on the BSE during the session, having begun the day stronger at Rs 5,202.00 compared to its previous close of Rs 5,082.35.

Russia has granted regulatory approval to a second COVID-19 vaccine, according to its register of authorised medicines.

The Hyderabad-based Dr Reddy's Laboratories has reapplied to the Drugs Controller General of India (DCGI) seeking permission to conduct combined phases 2 and 3 human clinical trials of the Russian COVID-19 vaccine Sputnik V in India.

Human trials of Russia's COVID-19 vaccine, named Sputnik V, will be held in the United Arab Emirates, the second country after Belarus to take part in the programme of which results are expected before the end of November, Moscow said on Monday.

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial, according to one of the outlets and four employees.

Russia's plan to roll-out its "Sputnik-V" COVID-19 vaccine even before full trials show how well it works is prompting concern among virus experts, who warn a partially effective shot may encourage the novel coronavirus to mutate.

Biotechnology industry veteran Kiran Mazumdar-Shaw has questioned Russian claims of developing the world's first safe coronavirus vaccine, citing absence of data on clinical trials and "more advanced" programmes elsewhere.

An announcement by Russia on Tuesday that it will approve a COVID-19 vaccine after less than two months of human testing prompted alarm among global health experts, who said that with no full trial data, the vaccine is hard to trust.

Russia said on Wednesday it planned to export a nasal form of its Sputnik vaccine against COVID-19, which President Vladimir Putin said he had taken as a booster.

The Russian COVID-19 vaccine "Sputnik V" will cost less than USD 10 (about Rs 730) per shot in India and the price is the same for all countries, Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) said on Thursday.

Congress's Rahul Gandhi today aimed a jibe at Prime Minister Narendra Modi, pointing to several nations beginning inoculation for Covid and implying India's journey towards a vaccine is slow. Four nations -- US, UK, China and Russia -- are pressing ahead with vaccination as a new, more infectious mutation of the virus has brought life to a standsti...

Russian coronavirus vaccine developers published fresh results from their trial of the Sputnik V vaccine on Monday based on new data, and said the shot had again been found to be 91.4 per cent effective in providing protection from COVID-19.

The first batch of Russia's Sputnik V vaccine for COVID-19 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine's Phase 2 and Phase 3 human clinical trials will be conducted.

Russia's Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country's sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

Pharmaceutical giant Dr. Reddy's Laboratories today said that it had isolated all its data centre services as a preventive measure following a cyberattack. The drug maker had shut its key plants globally due to the breach at its servers, ET Now had reported, citing sources.

Dr Reddy's Share Price: The stock rose by Rs 131.15 to Rs 5,213.50 apiece on the BSE during the session, having begun the day stronger at Rs 5,202.00 compared to its previous close of Rs 5,082.35.

Russia has granted regulatory approval to a second COVID-19 vaccine, according to its register of authorised medicines.

The Hyderabad-based Dr Reddy's Laboratories has reapplied to the Drugs Controller General of India (DCGI) seeking permission to conduct combined phases 2 and 3 human clinical trials of the Russian COVID-19 vaccine Sputnik V in India.

Human trials of Russia's COVID-19 vaccine, named Sputnik V, will be held in the United Arab Emirates, the second country after Belarus to take part in the programme of which results are expected before the end of November, Moscow said on Monday.

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial, according to one of the outlets and four employees.

Russia's plan to roll-out its "Sputnik-V" COVID-19 vaccine even before full trials show how well it works is prompting concern among virus experts, who warn a partially effective shot may encourage the novel coronavirus to mutate.

Biotechnology industry veteran Kiran Mazumdar-Shaw has questioned Russian claims of developing the world's first safe coronavirus vaccine, citing absence of data on clinical trials and "more advanced" programmes elsewhere.

An announcement by Russia on Tuesday that it will approve a COVID-19 vaccine after less than two months of human testing prompted alarm among global health experts, who said that with no full trial data, the vaccine is hard to trust.